{"filings":[{"id":1028836,"accession_number":"0001213900-26-068327","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2026-06-12T20:45:21+00:00","items":["8.01","9.01"],"status":"ready","headline":"NeuroOne files prospectus to sell up to $13.4M in common stock via ATM program with JonesTrading","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated prospectus supplement filed June 12, 2026 for at-the-market offering of up to $13.4M of common stock.","Shares to be sold through JonesTrading Institutional Services LLC under existing Capital on Demand Sales Agreement.","Program originally established December 2022; latest supplement updates the offering amount and conditions.","Legal opinion from Honigman LLP regarding the Shares is included as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":610402,"accession_number":"0001213900-26-060600","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2026-05-22T20:30:28+00:00","items":["4.02","7.01","9.01"],"status":"ready","headline":"NeuroOne restates Q1 FY2026 results due to revenue recognition error; reaffirms FY2026 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue overstated by ~$0.5M, net loss understated by ~$0.3M for quarter ended March 31, 2026.","Restatement caused by customer order modification at quarter-end; no prior periods affected.","Company reaffirms FY2026 product revenue guidance of at least $10.5M.","Internal control weakness identified; measures to improve controls are being implemented.","Audit Committee determined non-reliance on previously filed Form 10-Q for March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22802,"accession_number":"0001213900-26-054744","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2026-05-12T12:10:23+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroOne Q2 product revenue up 72% to $2.4M; net loss narrows to $2.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $2.4M (+72% YoY); no license revenue vs $3.0M in prior year first half.","Net loss $2.1M ($0.25/sh) vs $2.3M ($0.44/sh) in same quarter last year.","Cash $2.8M; working capital $5.7M; no debt outstanding; accounts receivable $2.4M.","16 trigeminal neuralgia cases completed with all patients reportedly pain free.","Christopher Volker to become CFO effective July 1, 2026; David Wambeke hired as CBO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":5283820.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93221,"accession_number":"0001213900-26-051158","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NeuroOne regains Nasdaq compliance as bid price holds above $1 for 10 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on May 6, 2025 for bid price below $1 for 30 consecutive days.","On April 30, 2026, Nasdaq notified company compliance regained after 10 consecutive days with closing bid price at or above $1.","Matter is closed; the company continues to trade on Nasdaq Capital Market.","No further action or extension required regarding the bid price rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93220,"accession_number":"0001213900-26-049748","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Ronald McClurg to retire June 30, 2026; COO Christopher Volker to succeed as CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ronald McClurg to retire as CFO effective June 30, 2026, then serve as Senior Advisor until Dec 31, 2026.","Christopher Volker, current COO, appointed CFO effective July 1, 2026; base salary increased to $350,000.","Volker brings medtech experience from Abbott, CSI, St. Jude Medical; holds Wharton MBA and CFA.","McClurg entered Transition and Release Agreement dated April 28, 2026; will receive salary/benefits through retirement and provide general release.","McClurg's equity awards (options/RSUs) continue per plan terms; no immediate change to equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93219,"accession_number":"0001213900-26-043239","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"NeuroOne to effect 1-for-6 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-6 reverse stock split, effective 5:00 p.m. ET on April 15, 2026.","Trading on Nasdaq will commence on split-adjusted basis under symbol NMTC on April 16, 2026.","No fractional shares; stockholders entitled to cash payment for fractional interests.","Reverse split intended to increase bid price and regain compliance with Nasdaq minimum bid rule.","Authorized shares and par value unchanged; CUSIP changes to 64130M308."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93218,"accession_number":"0001213900-26-039992","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NeuroOne shareholders approve reverse stock split and 1.5M share increase in equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse stock split at ratio of 1-for-2 to 1-for-15; board to determine final ratio.","Shareholders approved amendment to 2025 Equity Incentive Plan, increasing shares by 1,500,000 and adding 5% annual evergreen increase starting 2027.","Elected Jeffrey Mathiesen and Edward Andrle as Class III directors for three-year terms.","Ratified Baker Tilly US, LLP as independent auditor for fiscal year ending September 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104670,"accession_number":"0001213900-26-020400","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NeuroOne sets 2026 annual meeting for April 3; shareholder proposals due March 4","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for April 3, 2026; date moves more than 30 days from 2025 meeting.","Stockholder proposals under Rule 14a-8 must be received by March 4, 2026 for proxy inclusion.","Additional meeting details to be provided in the proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104669,"accession_number":"0001213900-26-016912","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroOne Q1 net loss $1.4M; guides FY26 product revenue at least $10.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 product revenue $2.9M (down 12% YoY, but up 5.5% sequentially from Q4 FY25).","Net loss $1.4M ($0.03/sh) vs net income $1.8M ($0.06/sh) in Q1 FY25 due to no license revenue.","Cash $3.6M as of Dec 31, 2025; funded through FY26 if milestones hit.","Completed 9 trigeminal neuralgia cases after FDA clearance; all patients reportedly pain free.","Expects FY26 product revenue of at least $10.5M, a 17% YoY increase from $9.1M."],"consensus_eps_estimate":-0.2312,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":2892635.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120955,"accession_number":"0001213900-25-124165","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeuroOne appoints Jason Mills, Penumbra EVP of Strategy, to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased to five; Mills appointed as Class I director effective Dec 18, 2025.","Mills will serve on Compensation and Nominating & Corporate Governance Committees.","Mills is EVP of Strategy at Penumbra (PEN), a leading thrombectomy company.","Previously Managing Director and head of med-tech research at Canaccord Genuity for 13+ years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120954,"accession_number":"0001213900-25-122541","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroOne reports Q4 product revenue of $2.7M (+907% YoY); full-year loss narrows 71%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $2.7M in Q4 FY2025, up 907% YoY; full year product revenue $9.1M, up 163% YoY.","Product gross margin improved to 55.8% in Q4 and 56.5% for FY2025, up from 31.3% in FY2024.","Net loss improved 71% to $3.6M ($0.09/share) for FY2025; Q4 net loss $1.6M ($0.03/share) vs $3.4M ($0.11) YoY.","FDA 510(k) clearance for OneRF Trigeminal Nerve Ablation System; first two trigeminal neuralgia patients treated.","Cash & equivalents $6.6M (up from $1.5M); no debt; funded through fiscal 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120953,"accession_number":"0001213900-25-106454","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"NeuroOne Medical receives Nasdaq extension to May 4, 2026 to regain $1.00 bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted a 180-day extension until May 4, 2026 for minimum bid price compliance.","Company previously disclosed non-compliance on May 9, 2025; initial cure period expired Nov 3, 2025.","If not compliant by May 4, 2026, Nasdaq may delist; company can appeal to a hearing panel.","Listing remains fully effective during extension; no immediate impact on common stock trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120952,"accession_number":"0001213900-25-096548","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"NeuroOne reports preliminary FY2025 product revenue of $9.1M, up 163% from $3.5M in FY2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited FY2025 product revenue $9.1M, a record; FY2024 was $3.5M.","Cash and equivalents $6.6M as of September 30, 2025.","Growth driven by expanded customer interest in OneRF Ablation system for epilepsy.","Complete financial results expected to be announced in December 2025.","Company to host virtual investor webinar on October 7, 2025 at 8:30am EST."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":9097692.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137543,"accession_number":"0001213900-25-077726","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NeuroOne receives FDA 510(k) clearance for OneRF Trigeminal Nerve Ablation System","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA 510(k) clearance granted for OneRF Trigeminal Nerve Ablation System.","System used for radiofrequency lesions to treat pain and functional neurosurgery.","Clearance announced on August 18, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137542,"accession_number":"0001213900-25-077511","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NeuroOne files prospectus supplement for up to $6.75M ATM offering via JonesTrading","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed updated Prospectus Supplement on Aug 15, 2025 for up to $6.75M of common stock via ATM.","Offering made under existing Capital on Demand Sales Agreement with JonesTrading (Dec 2022).","Legal opinion on shares attached as Exhibit 5.1; proceeds not specified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137541,"accession_number":"0001213900-25-076039","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroOne Q3 revenue up 105% to $1.7M; net loss narrows to $1.5M; FY25 guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $1.7M, up 105% YoY; gross margin 53.9% (vs 34.1%).","Net loss $1.5M ($0.03 EPS) vs $2.8M ($0.10 EPS); operating expenses down 9% to $2.8M.","Oversubscribed $8.2M capital raise closed April 2025; cash $8.0M, no debt.","FY2025 product revenue guidance $8-10M (132-190% growth); gross margin guidance raised to 50-53%.","Milestones: FDA 510(k) filed for trigeminal ablation; first patient seizure-free 1-year; sEEG drug delivery order."],"consensus_eps_estimate":-0.2448,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":6356767.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154910,"accession_number":"0001213900-25-042270","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NeuroOne Q2 net loss narrows to $2.3M; gross margin up to 55.6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 product revenue $1.4M flat YoY; H1 product revenue up 98% to $4.7M.","Q2 product gross margin 55.6% vs 28.3% YoY; FY25 guidance reaffirmed ($8-10M revenue).","Filed 510(k) for OneRF Trigeminal Nerve Ablation System for facial pain ahead of schedule; potential revenue in late CY2025.","Raised $8.2M net in oversubscribed institutional offering in April; cash $9.4M post-raise; debt-free.","Hired Dr. Parag Patil as Chief Medical Advisor and Emily Johns as General Counsel."],"consensus_eps_estimate":-0.306,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":4660717.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154909,"accession_number":"0001213900-25-041554","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"NeuroOne receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price was below $1.00 for 30 consecutive business days; 180-day cure period ends Nov. 3, 2025.","To regain compliance, stock must close at or above $1.00 for at least 10 consecutive business days.","If not cured by Nov. 3, may qualify for a second 180-day period if other initial listing standards are met.","Company says it will monitor and consider options but gives no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154908,"accession_number":"0001213900-25-029442","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"NeuroOne raises $8M in underwritten public offering of 16M shares at $0.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 16,000,000 shares at $0.50 per share; underwriter option for additional 2,400,000 shares.","Gross proceeds of $8.0M (excluding underwriter option); net proceeds for general working capital.","Post-offering shares outstanding increase to 49,797,000.","75-day lock-up on executive officers and directors for additional share sales.","Offering closed on April 7, 2025; Ladenburg Thalmann as sole underwriter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173427,"accession_number":"0001213900-25-015683","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K/A","filed_at":"2025-02-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NeuroOne stockholders approve 2025 Equity Incentive Plan and reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved 2025 Equity Incentive Plan authorizing up to 3M new shares plus returning shares from prior plan.","Approved reverse stock split at ratio of 1:2 to 1:15, with exact ratio to be set by the Board.","David Rosa re-elected as Class II director with 11.7M votes for, 381.7K withheld, 6.0M broker non-votes.","Ratified Baker Tilly U.S., LLP as independent auditor for FY2025 with 18.1M votes for, 7.4K against.","Adjournment proposal also approved, with 16.8M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173433,"accession_number":"0001213900-25-014281","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders elect Rosa, approve reverse stock split and 2025 equity plan at annual meeting.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David Rosa elected Class II director: 11,724,206 for, 381,677 against, 6,011,755 broker non-votes.","Baker Tilly U.S., LLP ratified as auditor: 18,080,780 for, 7,381 against, 29,477 abstain.","Reverse stock split approved (ratio 1-for-2 to 1-for-15): 16,176,833 for, 1,732,603 against.","2025 Equity Incentive Plan approved: 10,595,402 for, 1,473,888 against, 6,010,237 broker non-votes.","Adjournment authorization approved: 16,811,725 for, 1,270,013 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173432,"accession_number":"0001213900-25-012510","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroOne Q1 FY2025 revenue $6.3M, net income $1.8M; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $3.3M (+235% YoY); license revenue $3.0M from expanded Zimmer Biomet deal.","Net income $1.8M ($0.06 EPS) vs net loss of $3.3M ($0.14 loss) in prior year.","Product gross margin improved to 58.9% from 27.2%; FY2025 product revenue outlook $8-10M reaffirmed.","Regained Nasdaq compliance; debt-free with $1.1M cash and $4.1M working capital.","OneRF placed in 5 epilepsy centers; FDA 510(k) submission for trigeminal nerve ablation expected H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":3274167.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173431,"accession_number":"0001213900-25-010083","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NeuroOne regains Nasdaq compliance; reports record preliminary Q1 revenue of $6.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq letter on Feb 3, 2025 confirming cure of bid price deficiency; hearing cancelled.","Preliminary unaudited Q1 FY2025 total revenue of $6.2M (product $3.2M + one-time license $3.0M).","CEO highlights OneRF Ablation System as first FDA-cleared device for RF ablation in the brain.","Earnings call scheduled for February 12, 2025 at 8:30 am ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173430,"accession_number":"0001213900-25-003166","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeuroOne issues shareholder letter; no specific financial or operational metrics disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Dave Rosa discusses company achievements, progress, and strategy in letter dated Jan 14, 2025.","Letter does not contain specific revenue, earnings, or guidance figures.","Letter posted to company website and furnished under Regulation FD.","No material new information beyond general business update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173429,"accession_number":"0001213900-25-002728","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"NeuroOne receives Nasdaq delisting determination for bid price non-compliance; intends to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received delisting determination from Nasdaq on Jan 8, 2025 for continued non-compliance with $1.00 minimum bid price rule.","180-day compliance period ended Jan 7, 2025; company failed to regain compliance.","Company will request a hearing before Nasdaq Hearings Panel to appeal; hearing stays delisting action pending outcome.","Common stock (NMTC) remains listed and tradable at least until final hearing conclusion.","No assurance of regaining compliance or continued listing on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173428,"accession_number":"0001213900-25-002381","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NeuroOne reports preliminary Q1 FY2025 revenue of $6.2M, up from $1.0M YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited Q1 FY2025 total revenue $6.2M vs $1.0M in Q1 FY2024.","Includes $3.0M one-time collaboration revenue from Zimmer Biomet expanded distribution agreement.","Product revenue $3.2M, up 227% YoY from $1.0M.","Reiterates FY2025 product revenue guidance $8-10M, product gross margin 47-51%.","Virtual investor webinar held Jan 10, 2025 at 11am ET."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":3274167.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190423,"accession_number":"0001213900-24-109529","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"NeuroOne FY2024 product revenue $3.5M (+77%); FY2025 guidance $8-10M (+132-190%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue FY2024 $3.5M (+77% YoY); net loss $12.3M vs $11.9M prior year.","FY2025 product revenue guidance $8-10M (+132-190%); gross margin 47-51% vs 31% in FY2024.","Received $3M upfront from expanded Zimmer Biomet distribution agreement in Nov 2024; terminated $3M credit facility.","Net loss Q4 $3.3M vs $3.1M; operating expenses down 12% to $3.0M in Q4.","Nasdaq compliance: monitoring bid price until Jan 7, 2025; equity restored above $2.5M after Zimmer payment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190422,"accession_number":"0001213900-24-095934","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"NeuroOne terminates loan agreement with Growth Opportunity Funding effective Nov 7, 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["NeuroOne and Growth Opportunity Funding, LLC mutually terminated the Loan and Security Agreement dated August 2, 2024 on November 7, 2024.","As of termination date, the Company had no loan balance outstanding under the agreement.","The original Loan Agreement terms were disclosed in the Company's 8-K filed August 7, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190421,"accession_number":"0001213900-24-092879","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"NeuroOne expands Zimmer Biomet distribution deal for OneRF Ablation System; $3M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Zimmer Biomet gets exclusive US and certain OUS distribution rights for OneRF Ablation System.","NeuroOne receives $3M upfront within 10 business days plus up to $1M milestone payment.","OneRF is only FDA-cleared RF ablation system for both diagnostic and therapeutic brain use.","Agreement effective Oct 25, 2024, term to Sep 30, 2034 unless earlier terminated.","NeuroOne expects meaningful revenue and improved profitability from the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206926,"accession_number":"0001213900-24-078584","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NeuroOne amends CEO & three other execs' change-in-control severance benefits","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Rosa: 2.0x base salary + 2.0x target bonus lump sum, full equity vest, 24-month COBRA upon qualifying termination.","CFO McClurg, COO Volker, CTO Mertens: 1.25x base + 1.25x bonus lump sum, full vest, 15-month COBRA.","Amendments effective Sep 9, 2024; apply to terminations within 12 months after or 3 months before a change in control.","Benefit conditioned on signing a release and ongoing compliance; all other employment terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206925,"accession_number":"0001213900-24-069036","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroOne Q3 product rev up 31% to $826K; net loss narrows to $2.8M; oneRF partnership term sheet signed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $826K in Q3 FY2024 vs $630K in Q3 FY2023 (+31%); net loss $2.8M vs $3.5M.","Cash and equivalents $1.6M at June 30, 2024; subsequent $2.65M private placement and $3M credit facility in Aug 2024.","Non-binding term sheet with undisclosed global medtech company to distribute OneRF Ablation System.","First OneRF ablation cases completed; CMS granted new ICD-10-PCS code effective Oct 1, 2024.","Operating expenses reduced to $3.1M from $3.8M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":3180719.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206924,"accession_number":"0001213900-24-066142","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"NeuroOne raises ~$2.65M in private placement and secures $3M debt facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 2,944,446 shares and warrants for 2,208,333 shares at $0.90/unit, gross ~$2.65M.","Closed Aug 2, 2024. Proceeds for operations, commercial expansion, product development, and strategic partner diligence.","Also entered $3M delayed-draw term loan from Growth Opportunity Funding at 10% interest, maturing Feb 2, 2026.","Lender received warrant for 100,000 shares at $0.66, plus additional warrants upon draws.","Director Paul Buckman participated in private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206923,"accession_number":"0001213900-24-061064","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"NeuroOne receives Nasdaq delisting notice for bid price below $1.00 for 30 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price of common stock below $1.00 for 30 consecutive business days triggered Nasdaq minimum bid price deficiency.","Company has 180 calendar days, until January 7, 2025, to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant by Jan 7, 2025, may qualify for an additional 180-day period if it meets other listing standards.","NeuroOne intends to monitor bid price and consider available options to cure the deficiency; delisting risk remains if not cured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224200,"accession_number":"0001213900-24-054782","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"NeuroOne amends bylaws: reduces stockholder quorum to one-third, updates proxy rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholder quorum reduced from majority to one-third of outstanding voting power.","New universal proxy compliance requirement under SEC Rule 14a-19 for director nominations.","Enhanced disclosure obligations for stockholder nominations and proposals, including derivative interests.","Special meeting nominators must hold 10% of voting power and be stockholder at notice and record dates.","Clarified personal jurisdiction and service of process for foreign actions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224199,"accession_number":"0001213900-24-042938","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroOne Q2 FY2024 product revenue triples to $1.38M; OneRF ablation system launched","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $1.38M in Q2 2024, up from $466K in Q2 2023.","Net loss narrowed to $2.9M vs $3.5M a year ago; six-month net loss $6.2M.","Cash and cash equivalents $2.4M as of March 31, 2024, down from $5.3M at Sept 30, 2023.","Initiated limited commercial launch of OneRF Ablation System in late March; 5 patients implanted.","Zimmer Biomet continued expanding sEEG electrode accounts; raised $2.0M via ATM in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":2354943.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243546,"accession_number":"0001213900-24-025811","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NeuroOne Medical Technologies starts limited commercial launch of OneRF Ablation System","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OneRF System is FDA 510(k)-cleared for creating RF lesions in nervous tissue for functional neurosurgery.","CEO Dave Rosa expects shipping to begin this week with first cases scheduled in April 2024.","First therapeutic device for NeuroOne; third FDA 510(k)-cleared device alongside Evo electrode lines.","Company estimates the brain ablation market at least $100M worldwide with significant growth potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243545,"accession_number":"0001213900-24-023083","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"NeuroOne shareholders elect director, ratify auditor, approve exec compensation vote every three years","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Paul Buckman elected Class I director: 5,804,908 for, 1,363,109 withheld, 8,614,407 broker non-votes.","Ratification of Baker Tilly as independent auditor: 15,736,069 for, 36,991 against, 9,364 abstain.","Advisory approval of named executive officer compensation: 6,586,582 for, 330,506 against, 250,929 abstain.","Advisory vote on frequency of exec compensation votes: every three years selected (3,723,836 votes); board to implement that cycle.","60.89% of shares represented at meeting (15,782,424 of ~25.9M shares outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243544,"accession_number":"0001213900-24-013294","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroOne Q1 revenue jumps to $978k; OneRF Ablation System receives FDA clearance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $978k in Q1 fiscal 2024, up from $115k in Q1 2023.","Net loss $3.3M vs $1.7M YoY; cash $2.7M at Dec 31, 2023.","FDA 510(k) clearance for OneRF Ablation System in Dec 2023; limited commercial launch expected Q2 2024.","Zimmer Biomet sales force trained for Evo sEEG; new accounts expected to drive revenue growth.","Raised $2.8M via ATM offering at avg $1.45/share in Dec 2023 – Jan 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":977649.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260956,"accession_number":"0001213900-23-095741","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroOne Q4 product revenue $742K vs $69K YoY; net loss $3.1M; FDA clears OneRF Ablation System","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $742K (Q4) vs $69K YoY; full year $1.952M vs $171K.","Net loss $3.1M (Q4) vs $1.4M; full year $11.9M vs $10.0M.","Received FDA 510(k) clearance for OneRF Ablation System in Dec 2023; commercial launch expected H1 2024.","Cash $5.3M as of Sep 30, 2023, down from $11.1M; raised $5.2M net in public offering and $2.5M via ATM at $1.77/share.","Zimmer Biomet expanding Evo sEEG launch; device sales ramp expected quarter by quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260955,"accession_number":"0001213900-23-094562","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NeuroOne receives FDA 510(k) clearance for OneRF Ablation System; plans H1 2024 launch","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA 510(k) clearance for OneRF Ablation System to create RF lesions in nervous tissue for functional neurosurgical procedures.","First FDA-cleared thin-film, sEEG-guided RF system combining recording and ablation with temperature control; third FDA-cleared device.","Company targets commercial launch in first half of 2024, either directly or through a strategic partner.","Estimated worldwide brain ablation market at least $100M and growing rapidly, with potential for multifold growth.","Potential for patients to need only one surgery for both diagnostic and therapeutic procedures, reducing hospital stays and adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260954,"accession_number":"0001213900-23-087723","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NeuroOne receives Notice of Allowance for drug-delivery neural probe patent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO issued Notice of Allowance for Patent App. 16/812,702 covering electrodes that deliver treatment agent to brain target.","This is the third Notice of Allowance received by NeuroOne in recent months.","Company expects patent issuance in the coming months.","CEO says allowance strengthens IP portfolio and supports partnering for combination drug-delivery and sEEG recording.","NeuroOne's portfolio now includes 3 allowed apps, 1 issued patent, 8 pending U.S. apps, and several foreign apps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260953,"accession_number":"0001213900-23-087126","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"NeuroOne appoints medtech exec Christopher Volker as COO; inducement plan expanded by 420,350 shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Volker appointed COO effective Nov 10, 2023; formerly Head of Commercial Integration at Abbott and VP/GM International at Cardiovascular Systems.","Volker receives base salary of $288,000, 40% target bonus, and option to purchase 324,560 shares at $1.32 per share.","Inducement plan amended to increase reserved shares from 150,000 to 570,350 to attract qualified employees.","Option vests 25% after one year, then monthly over 36 months; accelerated vesting upon change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260952,"accession_number":"0001213900-23-084013","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NeuroOne responds to FDA questions on OneRF Ablation System 510(k); expects feedback in 30 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company responded to FDA questions on its 510(k) submission for the OneRF Ablation System.","FDA feedback expected within 30 days; commercialization targeted for H1 2024 pending clearance.","OneRF would be first sEEG-guided RF ablation system with real-time temperature control.","NeuroOne estimates worldwide brain ablation market at $100M+ with rapid growth potential.","CEO Dave Rosa cites potential to reduce hospital stays, procedures, and complications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278228,"accession_number":"0001213900-23-067061","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroOne Q3 FY2023 product revenue $630K, up from $32K; net loss $3.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $630K in Q3 FY2023 vs $32K YoY; collaboration revenue $1.46M in 9M.","Net loss $3.5M in Q3 vs $2.8M prior year; cash $3.1M at June 30 vs $8.1M at Sept 30.","Evo sEEG limited launch completed; full launch with Zimmer Biomet expected Q4. OneRF 510(k) submitted June 8.","Closed public offering net $5.2M and ATM net $2.5M in July 2023; no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":1210661.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278227,"accession_number":"0001213900-23-060256","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"NeuroOne raises ~$5.2M net in registered direct offering of 6M shares at $1.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered and sold 6,037,500 shares (including full overallotment) at $1.00 per share raising gross ~$6.04M.","Net proceeds of ~$5.215M after underwriting discounts and offering expenses.","Proceeds to fund EVO sEEG commercial launch with Zimmer Biomet, FDA filing for OneRF ablation, and drug-delivery electrode design.","Offering closed July 27, 2023; 90-day lock-up for insiders on further share sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296331,"accession_number":"0001213900-23-038538","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroOne Q2 product revenue surges to $466K; net loss $3.5M; Evo sEEG launched","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $466K in Q2 (vs $37K YoY); collaboration revenue $1.46M first half from Zimmer deal.","Net loss $3.5M for Q2 vs $3.1M prior year; operating expenses rose to $3.5M.","Cash and equivalents $4.6M as of Mar 31, down from $11.1M at Sep 30; no debt.","Commercial launch of Evo sEEG electrode with Zimmer Biomet; first cases at Mayo and Cleveland Clinic.","On track to submit 510(k) for OneRF ablation system in Q2 calendar 2023; new VP of Operations appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":580755.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316809,"accession_number":"0001213900-23-021037","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NeuroOne holds annual meeting; elects directors Mathiesen and Andrle, ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting held March 16, 2023; 9,719,474 shares (59.83%) represented.","Jeffrey Mathiesen re-elected as Class III director: 4,309,601 votes for, 268,402 withheld.","Edward Andrle re-elected as Class III director: 3,474,438 votes for, 1,103,565 withheld.","Baker Tilly U.S., LLP ratified as independent auditor for FY ending Sept 30, 2023: 9,661,674 for, 45,763 against, 12,037 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316808,"accession_number":"0001213900-23-019237","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"NeuroOne confirms no cash deposits or securities at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company states it holds no cash or securities at Silicon Valley Bank.","Disclosure comes amid SVB's collapse in March 2023.","No financial impact from SVB situation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316807,"accession_number":"0001213900-23-011512","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NeuroOne Q1 FY2023 net loss $1.7M; FDA cleared Evo sEEG electrode","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $115K (vs $34K YoY); collaboration revenue $1.46M from Zimmer agreement.","Net loss $1.7M (improved from $2.8M); cash $7.6M, no debt as of Dec 31, 2022.","FDA 510(k) clearance for Evo sEEG electrode; first commercial order shipped to Zimmer Biomet.","Targeting OneRF ablation system 510(k) submission in Q2 calendar 2023; spinal cord stimulation electrodes in pre-clinical.","R&D expense $1.6M (up from $1.1M); SG&A flat at $1.7M; total op ex $3.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":114579.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316806,"accession_number":"0001213900-23-002798","cik":1500198,"company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","ticker":"NMTC","form_type":"8-K","filed_at":"2023-01-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NeuroOne Medical appoints American Stock Transfer as new transfer agent","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Appointed American Stock Transfer & Trust Company effective January 9, 2023.","All registered common shares moved from Securities Transfer Corporation.","New transfer agent contact: 800-937-5449, Brooklyn, NY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":32798627.690348532,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-13T23:59:59+00:00|316806"}